Quality measures in HCC care by the Practice Metrics Committee of the American Association for the Study of Liver Diseases

Sumeet K. Asrani, Marwan S. Ghabril, Alexander Kuo, Raphael B. Merriman, Timothy Morgan, Neehar D. Parikh, Nadia Ovchinsky, Fasiha Kanwal, Michael L. Volk, Chanda Ho, Marina Serper, Shivang Mehta, Vatche Agopian, Roniel Cabrera, Victoria Chernyak, Hashem B. El‐Serag, Julie Heimbach, George N. Ioannou, David Kaplan, Jorge Marrero, Neil Mehta, Amit Singal, Riad Salem, Tamar Taddei, Anne M. Walling, Elliot B. Tapper – 14 November 2021 – The burden of HCC is substantial.

Predicting Liver‐Related Outcomes in People With Nonalcoholic Fatty Liver Disease: The Prognostic Value of Noninvasive Fibrosis Tests

Amy L. Johnson, Kelly L. Hayward, Preya Patel, Leigh U. Horsfall, Alvin Ee Zhiun Cheah, Katharine M. Irvine, Anthony W. Russell, Katherine A. Stuart, Sue Williams, Gunter Hartel, Patricia C. Valery, Elizabeth E. Powell – 14 November 2021 – It remains unclear whether screening for advanced fibrosis in the community can identify the subgroup of people with nonalcoholic fatty liver disease (NAFLD) at higher risk for development of liver‐related complications.

An Analysis of Free‐Text Refusals as an Indicator of Readiness to Accept Organ Offers in Liver Transplantation

Jin Ge, Elaine Ku, Garrett R. Roll, Jennifer C. Lai – 14 November 2021 – Racial/ethnic minorities experience higher rates of wait‐list mortality and longer waiting times on the liver transplant wait list. We hypothesized that racial/ethnic minorities may encounter greater logistical barriers to maintaining “readiness” on the wait list, as reflected in offer nonacceptance. We identified all candidates who received an organ offer between 2009 and 2018 and investigated candidates who did not accept an organ offer using a free‐text refusal reason associated with refusal code 801.

Presence of Liver Inflammation in Asian Patients With Chronic Hepatitis B With Normal ALT and Detectable HBV DNA in Absence of Liver Fibrosis

Jiacheng Liu, Jian Wang, Xiaomin Yan, Ruifei Xue, Jie Zhan, Suling Jiang, Yu Geng, Yilin Liu, Minxin Mao, Juan Xia, Shengxia Yin, Xin Tong, Yuxin Chen, Weimao Ding, Rui Huang, Chao Wu – 14 November 2021 – Liver biopsies are recommended to exclude significant liver inflammation in patients with chronic hepatitis B (CHB) with elevated HBV DNA but without other indications for antiviral treatment. We aimed to investigate the proportions and determinants of significant inflammation in Asian patients with CHB with detectable HBV DNA.

PSMA as a Theranostic Target in Hepatocellular Carcinoma: Immunohistochemistry and 68Ga‐PSMA‐11 PET Using Cyclotron‐Produced 68Ga

Scott M. Thompson, Garima Suman, Michael S. Torbenson, Zong‐Ming E. Chen, Danielle E. Jondal, Anurima Patra, Eric C. Ehman, James C. Andrews, Chad J. Fleming, Brian T. Welch, Anil N. Kurup, Lewis R. Roberts, Kymberly D. Watt, Mark J. Truty, Sean P. Cleary, Rory L. Smoot, Julie K. Heimbach, Nguyen H. Tran, Amit Mahipal, Jun Yin, Tyler Zemla, Chen Wang, Zachary Fogarty, Mark Jacobson, Bradley J. Kemp, Sudhakar K. Venkatesh, Geoffrey B. Johnson, David A. Woodrum, Ajit H.

Subscribe to